Category: Health and wellness

FN Media Group Presents Safehaven.com News Commentary

Wayland Group (WAYL.CN – MRRCF) can produce cannabis at $0.05 a gram in South American and sells cannabis for up to $16 in some European markets. How do they do it? With a simple, but powerful business strategy. Mentioned in today”s commentary includes: Canopy Growth Corporation (NYSE: CGC) (TSX: WEED), Cronos Group (NASDAQ: CRON) (TSX: CRON), Aurora Cannabis (NYSE: ACB) (TSX: ACB), Emblem Corp. (OTC: EMMBF) (TSX.V: EMC), THC Biomed International (OTC: THCBF) (CSE: THC).

Wayland focuses on the lowest cost production methods. Produce product in countries with weaker currencies. Sell into the highest-paying markets that have strong currencies. And don”t think because they focus on lowering the cost of production that this is a lower grade product.

Because the Wayland Group (WAYL.CN ; MRRCF) just hit one of the greatest benchmarks a cannabis producer can hit. They”ve achieved GMP Certification (Good Manufacturing Practice). The only other 4 Canadian cannabis producers who hit this milestone are industry giants now.

If you know cannabis investing, then you know these names:

  • Aurora Cannabis Inc now about $5.64 a share
  • Cronos Group Inc now about $11.35 a share
  • Canopy Growth Corporation now about $29.61 a share
  • Tilray, Inc now about $74 a share

Wayland has joined them as one of only 5 Canadian producers who are GMP certified producers for the European Union. It”s impressive because Wayland”s a much smaller company.

Why does the ability to sell into the European Union matter? Two reasons: First, because medical cannabis in Europe commands some of the highest prices per gram in the world. The insurance coverage in Europe for medical use of cannabis is widespread. Second, because of the currency exchange. Canadian producers are bearing production costs in Canadian dollars but selling in Euros. (One euro is worth roughly $1.52 Canadian.)

That is part of the reason why, in Canada, Wayland sells cannabis at an average $5.56 per gram. But in Europe Wayland (WAYL.CN; MRRCF) can sell it for up to $16 Canadian dollars per gram. That”s three times the price.

Wayland has taken this idea of low-cost production and high buying markets to an extreme their investors love

They automated production to reduce their workforce from 500 people down to just 26. And payroll costs can add enormous amounts to a company”s overhead (and eat away at margins).

For instance, the minimum wage in Canada is $14 per hour. And paying 500 people at $14 per hour for a 40-hour work week means you”re paying $280,000 per week in payroll. Over 52 weeks that balloons to over $14 million in payroll costs. But not at Wayland. By reducing staff to just 25 employees at a production facility through automation they”ve dramatically reduced costs.

The 4 cost-cutting secrets to these gross margins

  1. Technology is on their side

Wayland uses an AI Master Grower so they only need a fraction of the workforce of many labor intensive operations.

This cannabis producer has a world-class tech team. By using artificial intelligence and big data they have automated cannabis production to an astounding degree. Some of their competitors need up to 500 employees to match the production of Wayland”s staff of 26. That”s 5% of some competitors” workforce.

  2. Smart strategic alliances

The AI Master Grower is powered by Rockwell Automation, and Wayland is the first cannabis company to embrace automation as a key feature of the cultivation process. With a tiny staff, Wayland can produce thousands of grams of cannabis for export.
That brings production costs way, way down. At the Langton facility in Canada, Wayland deploys the AI Master Grower to oversee 365,000 square feet and a potential annual capacity of 95,000 kilos.

  3. They cut energy costs to a fraction

When cannabis was illegal, one way police would look for growers was to find places with massive energy costs. That”s because traditional production methods require enormous amounts of energy. Those costs cut into profits.
Wayland went through every step and cost of production to find ways to cut costs. The company can cut big costs by embracing renewable energy sources and energy efficient practices. Their facilities are powered by natural gas co-generation and they utilize recycled water for their hydroponics, which cuts down on waste that can accumulate from bad growth practices. The company has worked out a quick-dry method with former JPL scientists.

  4. VESIsorb Tech means customers need to take less to get the same effect

Wayland has also brought advances in pharmaceuticals to cannabis cultivation. The company has deployed VESIsorb medical tech for its cannabis products.
When cannabinoids are ingested, they enter the body but tend to get clumped in the digestive system, interfering with absorption and diminishing the overall effect. VESIsorb disperses the CBD molecules so they”re easier to absorb, providing higher and more immediate levels of CBD absorption. The company”s automated production techniques, energy efficiency and global reach means it can get its product to the market at a cost lower than many competitors all around the world.

In 2019, cannabis will enter the mainstream. Demand is set to grow. And Wayland”s low production costs will give it an edge over its competitors.

Savvy investors need pay attention.

Other companies transforming the cannabis sector:

Aurora Cannabis (NYSE:ACB) (TSX:ACB)

Recently, Aurora sealed a supply deal with Mexico”s Farmacias Magistrales SA, the country”s first and, for now, at least, only federally licensed importer of raw materials containing THC.

In an announcement from Aurora, the company stated that the deal ‘firmly establishes Aurora”s first-mover advantage in one of the world”s most populous countries, where more than 130 million people will have federally legal access to a range of Aurora”s non-flower medical cannabis products containing THC.’

Cronos Group (NASDAQ: CRON) (TSX: CRON)

The Canadian firm, though primarily an equity investor, has made some major moves in recent years, wheeling and dealing with some of the hottest names in the sector. Because of its forward-thinking attitude, it has drawn the attention of many major mainstream players, including the company behind Marlboro, Altria Group.

On December 7th, rumors were finally confirmed when Cronos made the official announcement of a C$2.4 billion strategic investment from Altria. ‘Altria is the ideal partner for Cronos Group, providing the resources and expertise we need to meaningfully accelerate our strategic growth,’ said Cronos Group”s Mike Gorenstein, Chairman, President and Chief Executive Officer.

Canopy Growth Corporation (NYSE:CGC) (TSX:WEED)

Canopy has not stopped making moves in the market, most recently swallowing up renowned vaporizer producer Stor & Bickel Gmbh & Co., the creator of the iconic Volcano® Medic and the Mighty® Medic devices

The €145 million all-cash deal makes it one of the largest in the marijuana sector this year, and Canopy Growth is not likely to stop there.

Emblem Corp. (OTCMKTS:EMMBF) (TSX.V: EMC)

Recently, Emblem completed testing on a new oral extended release product with partner Canntab Therapeutics. With the successful tests, the companies announced that they will be moving forward into clinical trials.

In addition to its advancements in the medial field, Emblem is also working towards a safer community, partnering with DriveABLE in an effort to curb accidents from impaired drivers. Nick Dean, CEO, Emblem Corp. explained, ‘Impairment – whether from alcohol, cannabis, fatigue, underlying medical conditions, or narcotics – is a serious issue that affects safety on roads and in the workplace.’

THC Biomed International (OTCMKTS:THCBF) (CSE:THC)

THC Biomed operates as a licensed producer under Canada”s Marihuana for Medical Purposes Regulations. It is also engaged in the research & development of the products and services to medical marijuana.

THC Biomed”s recently announced a new THC-based beverage, aiming to appeal to a broader range of consumers. John Miller CEO explained, ‘THC has conducted extensive research on cannabis edibles and beverages and I have found our product to be exclusive in its category.’

Though THC Biomed may be smaller than some of its more well-known competitors, it is just as ambitious. And it”s beginning to pay off. Earlier this month, the company made its first shipment of cannabis products to its Saskatchewan partner, and is rapidly expanding its holdings, with two new strata lot purchases, adding to its growing array of assets.

By. Joao Piexe

**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**

Notice for Forward-Looking Information

Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes that cannabis use and sales will grow as currently predicted; Wayland”s intended acquisition of various foreign companies and expansion into international markets; Wayland”s plans to bring automation and the latest technology to projects in various locations throughout the world; that it could be granted growing licenses; that Wayland can close on its announced purchases and joint ventures; that through efficiency and technology Wayland can substantially lower its production costs below competitors; that Wayland can sell its product at huge gross margins; that Wayland will create a range of cannabis consumer brands, to be distributed through their own digital platforms and retail facilities; that Wayland can successfully integrate pharmaceutical breakthroughs into its products; that Wayland can achieve its sales targets and gross profit margins as planned; and that it will be able to carry out its business plans.

Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Wayland. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sales are not obtained or are obtained subject to conditions that are not anticipated; growing competition for intended acquisitions in the cannabis industry; announced or expected acquisitions or joint ventures may not close because of inability to come to final terms, or inability to obtain regulatory compliance; potential future competition in the markets Wayland operates for sales; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; interruption or failure of information or other technology systems; the cannabis market may not grow as expected; Wayland”s technology and drive for efficiency may not achieve the expected results and its accomplishments may be limited; Wayland may not successfully develop a cannabis consumer brand; and it may not be successful in developing a cannabis based treatment for medical uses; even if it develops a successful treatment, it may not be able to protect its intellectual property; its patent applications may be rejected or successfully challenged; Wayland”s business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; incubator risk investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal laws; and regulatory risks relating to Wayland”s business, financings and strategic acquisitions.

DISCLAIMERS

PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. Safehaven.com, Leacap Ltd, and their owners, managers, employees, and assigns (collectively ‘the Company’) has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by Wayland fifty-eight thousand three hundred thirty three US dollars for this article and certain banner ads. This compensation is a major conflict with our ability to be unbiased, more specifically:

This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by Wayland to conduct investor awareness advertising and marketing for Wayland. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the company. The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public and non-public sources but is not researched or verified in any way whatsoever to ensure the information is correct.

SHARE OWNERSHIP. The owner of Safehaven.com will not notify the market when it decides to buy or sell shares of this issuer in the market. The owner of Safehaven.com will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing The Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don”t trade with money you can”t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.

DISCLAIMER: Safehaven.com is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with Safehaven.com or any company mentioned herein. The commentary, views and opinions expressed in this release by Safehaven.com are solely those of Safehaven.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains ‘forward-looking statements’ within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. ‘Forward-looking statements’ describe future expectations, plans, results, or strategies and are generally preceded by words such as ‘may’, ‘future’, ‘plan’ or ‘planned’, ‘will’ or ‘should’, ‘expected,’ ‘anticipates’, ‘draft’, ‘eventually’ or ‘projected’. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company”s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:
Media Contact – FN Media Group LLC
e-mail:  editor@financialnewsmedia.com  
U.S. Phone: +1(954)345-0611

LONDON, December 21, 2018 /PRNewswire/ —

Read Full Article

According to the new market research report Artificial Intelligence in Healthcare Market by Offering (Hardware, Software, Services), Technology (Machine Learning, NLP, Context-Aware Computing, Computer Vision), End-Use Application, End User, and Geography Global Forecast to 2025, published by MarketsandMarkets™, the Artificial Intelligence In Healthcare Market is estimated to be valued at USD 2.1 billion in 2018 and is expected to reach USD 36.1 billion by 2025, at a CAGR of 50.2% from 2018 to 2025. The market has huge potential across various end users such as hospitals and providers, healthcare payers, and pharmaceutical and biotechnology companies. Increasingly large and complex data set available in the form of big data and growing need to reduce the increasing healthcare cost drive the growth of this market. Improving computing power and declining cost of hardware are other key factors driving the AI in healthcare market.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=54679303

AI in healthcare market for software to hold largest market during forecast period 

The AI in healthcare market for software segment is expected to hold the largest market from 2018 to 2023. Growing adoption of AI solutions and platforms among healthcare providers and healthcare payers is the prime factor driving the growth of the software segment. The software is developed using AI technologies, such as machine learning, natural language processing, and deep learning. In most cases, the software can run in the existing system without any additional requirement for specific hardware.

Machine learning technology to witness highest CAGR from 2018 to 2025 

Machine learning technology is expected to hold the largest market share throughout the forecast period. Increasing adoption of machine learning technology (especially deep learning) in various healthcare applications is driving the growth of machine learning technology in AI in healthcare market. The major types of machine learning technology are deep learning, supervised learning, unsupervised learning, and reinforcement learning.

Browse in-depth TOC on Artificial Intelligence in Healthcare Market

65 Tables  

49 Figures  

216 Pages  

North America leads AI in healthcare market in terms of value 

North America to account for the largest size of the AI in healthcare market throughout the forecast period. The wide-scale adoption of AI technologies across the continuum of care, especially in the US, is the key factor supporting the growth of the AI in healthcare market in this region. In addition, the strong presence of key AI hardware and software providers, such as NVIDIA (US), Intel (US), Xilinx (US), Microsoft (US), AWS (US), Google (US), IBM (US), Johnson and Johnson (US), and GE (US), is complementing the growth of the AI in healthcare market in the region.

Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=54679303    

The major companies profiled in this report are NVIDIA (US), Intel (US), IBM (US), Google (US), Microsoft (US), AWS (US), General Vision (US), GE Healthcare (US), Siemens Healthineers (Germany), Medtronic plc (US). The market has active participation of start-ups. A few emerging companies in the market are CloudMedx (US), Imagia Cybernetics (Canada), Precision Health AI (US), and Cloud  Pharmaceuticals (US).

Please Explore Relevant Report Artificial Intelligence Market also.

About MarketsandMarkets™  

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com  

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/artificial-intelligence-healthcare-market.asp

Visit Our Web Site: https://www.marketsandmarkets.com

CHICAGO, December 17, 2018 /PRNewswire/ —

Read Full Article

According to the new market research report Artificial Intelligence in Healthcare Market by Offering (Hardware, Software, Services), Technology (Machine Learning, NLP, Context-Aware Computing, Computer Vision), End-Use Application, End User, and Geography Global Forecast to 2025, published by MarketsandMarkets™, the Artificial Intelligence In Healthcare Market is estimated to be valued at USD 2.1 billion in 2018 and is expected to reach USD 36.1 billion by 2025, at a CAGR of 50.2% from 2018 to 2025. The market has huge potential across various end users such as hospitals and providers, healthcare payers, and pharmaceutical and biotechnology companies. Increasingly large and complex data set available in the form of big data and growing need to reduce the increasing healthcare cost drive the growth of this market. Improving computing power and declining cost of hardware are other key factors driving the AI in healthcare market.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=54679303

AI in healthcare market for software to hold largest market during forecast period 

The AI in healthcare market for software segment is expected to hold the largest market from 2018 to 2023. Growing adoption of AI solutions and platforms among healthcare providers and healthcare payers is the prime factor driving the growth of the software segment. The software is developed using AI technologies, such as machine learning, natural language processing, and deep learning. In most cases, the software can run in the existing system without any additional requirement for specific hardware.

Machine learning technology to witness highest CAGR from 2018 to 2025 

Machine learning technology is expected to hold the largest market share throughout the forecast period. Increasing adoption of machine learning technology (especially deep learning) in various healthcare applications is driving the growth of machine learning technology in AI in healthcare market. The major types of machine learning technology are deep learning, supervised learning, unsupervised learning, and reinforcement learning.

Browse in-depth TOC on Artificial Intelligence in Healthcare Market

65 Tables  

49 Figures  

216 Pages  

North America leads AI in healthcare market in terms of value 

North America to account for the largest size of the AI in healthcare market throughout the forecast period. The wide-scale adoption of AI technologies across the continuum of care, especially in the US, is the key factor supporting the growth of the AI in healthcare market in this region. In addition, the strong presence of key AI hardware and software providers, such as NVIDIA (US), Intel (US), Xilinx (US), Microsoft (US), AWS (US), Google (US), IBM (US), Johnson and Johnson (US), and GE (US), is complementing the growth of the AI in healthcare market in the region.

Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=54679303    

The major companies profiled in this report are NVIDIA (US), Intel (US), IBM (US), Google (US), Microsoft (US), AWS (US), General Vision (US), GE Healthcare (US), Siemens Healthineers (Germany), Medtronic plc (US). The market has active participation of start-ups. A few emerging companies in the market are CloudMedx (US), Imagia Cybernetics (Canada), Precision Health AI (US), and Cloud  Pharmaceuticals (US).

Please Explore Relevant Report Artificial Intelligence Market also.

About MarketsandMarkets™  

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com  

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/artificial-intelligence-healthcare-market.asp

Visit Our Web Site: https://www.marketsandmarkets.com

CHICAGO, December 17, 2018 /PRNewswire/ —

Read Full Article

According to the new market research report Artificial Intelligence in Healthcare Market by Offering (Hardware, Software, Services), Technology (Machine Learning, NLP, Context-Aware Computing, Computer Vision), End-Use Application, End User, and Geography Global Forecast to 2025, published by MarketsandMarkets™, the Artificial Intelligence In Healthcare Market is estimated to be valued at USD 2.1 billion in 2018 and is expected to reach USD 36.1 billion by 2025, at a CAGR of 50.2% from 2018 to 2025. The market has huge potential across various end users such as hospitals and providers, healthcare payers, and pharmaceutical and biotechnology companies. Increasingly large and complex data set available in the form of big data and growing need to reduce the increasing healthcare cost drive the growth of this market. Improving computing power and declining cost of hardware are other key factors driving the AI in healthcare market.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=54679303

AI in healthcare market for software to hold largest market during forecast period 

The AI in healthcare market for software segment is expected to hold the largest market from 2018 to 2023. Growing adoption of AI solutions and platforms among healthcare providers and healthcare payers is the prime factor driving the growth of the software segment. The software is developed using AI technologies, such as machine learning, natural language processing, and deep learning. In most cases, the software can run in the existing system without any additional requirement for specific hardware.

Machine learning technology to witness highest CAGR from 2018 to 2025 

Machine learning technology is expected to hold the largest market share throughout the forecast period. Increasing adoption of machine learning technology (especially deep learning) in various healthcare applications is driving the growth of machine learning technology in AI in healthcare market. The major types of machine learning technology are deep learning, supervised learning, unsupervised learning, and reinforcement learning.

Browse in-depth TOC on Artificial Intelligence in Healthcare Market

65 Tables  

49 Figures  

216 Pages  

North America leads AI in healthcare market in terms of value 

North America to account for the largest size of the AI in healthcare market throughout the forecast period. The wide-scale adoption of AI technologies across the continuum of care, especially in the US, is the key factor supporting the growth of the AI in healthcare market in this region. In addition, the strong presence of key AI hardware and software providers, such as NVIDIA (US), Intel (US), Xilinx (US), Microsoft (US), AWS (US), Google (US), IBM (US), Johnson and Johnson (US), and GE (US), is complementing the growth of the AI in healthcare market in the region.

Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=54679303    

The major companies profiled in this report are NVIDIA (US), Intel (US), IBM (US), Google (US), Microsoft (US), AWS (US), General Vision (US), GE Healthcare (US), Siemens Healthineers (Germany), Medtronic plc (US). The market has active participation of start-ups. A few emerging companies in the market are CloudMedx (US), Imagia Cybernetics (Canada), Precision Health AI (US), and Cloud  Pharmaceuticals (US).

Please Explore Relevant Report Artificial Intelligence Market also.

About MarketsandMarkets™  

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com  

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/artificial-intelligence-healthcare-market.asp

Visit Our Web Site: https://www.marketsandmarkets.com

CHICAGO, December 17, 2018 /PRNewswire/ —

Read Full Article

According to the new market research report Artificial Intelligence in Healthcare Market by Offering (Hardware, Software, Services), Technology (Machine Learning, NLP, Context-Aware Computing, Computer Vision), End-Use Application, End User, and Geography Global Forecast to 2025, published by MarketsandMarkets™, the Artificial Intelligence In Healthcare Market is estimated to be valued at USD 2.1 billion in 2018 and is expected to reach USD 36.1 billion by 2025, at a CAGR of 50.2% from 2018 to 2025. The market has huge potential across various end users such as hospitals and providers, healthcare payers, and pharmaceutical and biotechnology companies. Increasingly large and complex data set available in the form of big data and growing need to reduce the increasing healthcare cost drive the growth of this market. Improving computing power and declining cost of hardware are other key factors driving the AI in healthcare market.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=54679303

AI in healthcare market for software to hold largest market during forecast period 

The AI in healthcare market for software segment is expected to hold the largest market from 2018 to 2023. Growing adoption of AI solutions and platforms among healthcare providers and healthcare payers is the prime factor driving the growth of the software segment. The software is developed using AI technologies, such as machine learning, natural language processing, and deep learning. In most cases, the software can run in the existing system without any additional requirement for specific hardware.

Machine learning technology to witness highest CAGR from 2018 to 2025 

Machine learning technology is expected to hold the largest market share throughout the forecast period. Increasing adoption of machine learning technology (especially deep learning) in various healthcare applications is driving the growth of machine learning technology in AI in healthcare market. The major types of machine learning technology are deep learning, supervised learning, unsupervised learning, and reinforcement learning.

Browse in-depth TOC on Artificial Intelligence in Healthcare Market

65 Tables  

49 Figures  

216 Pages  

North America leads AI in healthcare market in terms of value 

North America to account for the largest size of the AI in healthcare market throughout the forecast period. The wide-scale adoption of AI technologies across the continuum of care, especially in the US, is the key factor supporting the growth of the AI in healthcare market in this region. In addition, the strong presence of key AI hardware and software providers, such as NVIDIA (US), Intel (US), Xilinx (US), Microsoft (US), AWS (US), Google (US), IBM (US), Johnson and Johnson (US), and GE (US), is complementing the growth of the AI in healthcare market in the region.

Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=54679303    

The major companies profiled in this report are NVIDIA (US), Intel (US), IBM (US), Google (US), Microsoft (US), AWS (US), General Vision (US), GE Healthcare (US), Siemens Healthineers (Germany), Medtronic plc (US). The market has active participation of start-ups. A few emerging companies in the market are CloudMedx (US), Imagia Cybernetics (Canada), Precision Health AI (US), and Cloud  Pharmaceuticals (US).

Please Explore Relevant Report Artificial Intelligence Market also.

About MarketsandMarkets™  

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com  

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/artificial-intelligence-healthcare-market.asp

Visit Our Web Site: https://www.marketsandmarkets.com

CHICAGO, December 17, 2018 /PRNewswire/ —

Read Full Article

TauRx, a leader in neurodegenerative disease research, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LMTX® for the ‘treatment of frontotemporal dementia’. The term Frontotemporal Dementia (FTD) covers a number of sub-types of dementia, all of which are characterized by a progressive loss of neurons in the frontal and/or temporal lobes of the brain.

     (Logo: http://mma.prnewswire.com/media/609663/TauRx_Therapeutics_Logo.jpg )

LMTX® is the first protein aggregation inhibitor to reach Phase 3 clinical development for treatment of neurodegenerative diseases of the brain and was developed by TauRx based on nearly 30 years of research. Protein aggregation inhibitors work by undoing the protein aggregations in the brain that are now widely accepted to drive the development of dementia. This unique mechanism of action can potentially slow the rate of spread of the underlying disease pathology and thereby help to preserve patients” cognition, function and quality of life. Primarily focused at tangled sub-units of the tau protein, the active moiety in LMTX® has also shown to be active against aggregations of the TDP-43 protein; tau and TDP-43 aggregation is causative in most of the FTD sub-types.

‘The FDA orphan drug designation of LMTX® is another positive step for patients, clinical researchers and care teams, and it reinforces our continuing research for a disease-modifying treatment for this poorly-addressed family of rare neurodegenerative conditions,’ said Prof. Claude Wischik, Executive Chairman of TauRx and Professor of Old Age Psychiatry at the University of Aberdeen. LMTX® was granted Orphan Designations in this field by the EMA in 2010.

The FDA only grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US, or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug. ODD provides an incentive for sponsors to develop products for rare diseases.

About Frontotemporal Dementia  

Frontotemporal dementia (FTD) is a neurodegenerative syndrome characterised by progressive deficits in behaviour, mental function, and language. Behavioural variant FTD (bvFTD) is the most common type of FTD; it is particularly aggressive and progresses faster than Alzheimer”s disease.[1] Symptoms of bvFTD usually start at around 40-60 years of age. The most obvious early symptoms are personality changes, disinhibition, and apathy. This includes socially inappropriate behaviour, impulsive actions, reckless financial decisions and even criminal behaviour.[1] There are currently no treatments available that can affect the progression of FTD. Instead, treatments are aimed at modifying behavioural symptoms.

About TauRx Therapeutics Ltd 

TauRx Therapeutics Ltd is a member of the TauRx Pharmaceuticals group which is developing technology spun-out from the University of Aberdeen, Scotland, and was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases. The company”s tau aggregation inhibitor, LMTX®, targets aggregates of abnormal fibres of tau protein that form inside nerve cells in the brain, giving rise to ”tau tangles”. LMTX® has also been found to have effects on the aggregation of TDP-43 protein. TauRx”s headquarters are in Singapore and its primary research facilities are based in Aberdeen. For more information, please visit: http://www.taurx.com.

References 

  1. Bang J, et al. (2015) Frontotemporal dementia. Lancet 386:1672-82.

Website: http://www.taurx.com

ABERDEEN, Scotland and SINGAPORE, December 10, 2018 /PRNewswire/ —

Read Full Article

The global injection pens/injectable pens/pen injectors market is expected to reach USD 67.9 billion by 2025, according to a new report by Grand View Research, Inc., registering a 9.4% CAGR during the forecast period. High demand for these devices for management of various chronic as well as acute diseases and increasing awareness in developing regions are key factors expected to drive the market.

     (Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )

Injectable pens have witnessed significant success in improving patient convenience during management of chronic disease, a process that might include administering intermittent injections. These devices are more convenient and affordable than other delivery systems. Ongoing studies on the same to assess their applications in management of other diseases, including but not limited to Hepatitis C and cancer, is expected to ensure swift market growth through 2025.

Browse full research report with TOC on Injection Pens Market Size, Share & Trends Analysis Report By Product (Disposable, Reusable), By Dosage (Fixed, Variable), By Application, And Segment Forecasts, 2018 – 2025 at: https://www.grandviewresearch.com/industry-analysis/injection-pens-market

Further Key Findings From the Report Suggest: 

  • Rising incidence of diseases such as diabetes and arthritis is primarily boosting market growth
  • Increase in government healthcare expenditure and availability of favorable healthcare insurance policies in developed as well as developing countries is driving the market
  • By product, reusable injectable pens are the largest and fastest growing segment owing to the advantages associated with them such as cost effectiveness and patient convenience. Commercially available reusable injectable pens mainly include Novopen, Luxura, Berlipen, AllStar, NovoRapid, basalgar, Bydureon, Epipen and Genotropin
  • By dosage, variable dosage is the fastest growing segment. Some of the customizable variable pens are UnoPen, ServoPen and Ypsopen by Ypsomed, Madie by SHL Group, and Evo pen by Copernicus
  • North America dominates the market, followed by Europe. Technological advancements and increase in incidence of osteoporosis, arthritis, and anaphylaxis are factors that can be attributable to its largest market share
  • Asia Pacific is expected to be the fastest growing region over the forecast period. Better accessibility to healthcare, coupled with constantly increasing healthcare expenditure in the region, is fueling market growth
  • China is one of the most lucrative markets with tremendous growth opportunities for global as well as local players. This is owing to favorable factors such as availability of labor and raw materials at significantly lower prices as compared to other regions
  • Key players in the market include Owen Mumford Ltd.; GlaxoSmithKline plc; Eli Lilly and Company; Mylan N.V.; AstraZeneca; Novo Nordisk; Sanofi; and Sandoz Inc.

Browse related reports by Grand View Research: 

  • Reprocessed Medical Devices Market The global reprocessed medical devices market size was estimated at USD 1.64 billion in 2016 and is anticipated to grow at a CAGR of 20.6% over the forecast period.
  • Electroceuticals/Bioelectric Medicine Market The global electroceuticals/bioelectric medicine market size was estimated at USD 17.2 billion in 2016.
  • Biosensors Market The global biosensors market size was valued at USD 15.6 billion in 2016 and is expected grow at a CAGR of 7.9% during the forecast period.
  • Bone Densitometers Market The global bone densitometers market size was estimated at USD 893.7 million in 2016 and is expected to grow at a CAGR of 3.9% over the coming years.

Grand View Research has segmented the global injection pens market on the basis of product, dosage, application, and region: 

  • Injection Pens Product Outlook (Revenue, USD Billion, 2014 – 2025) 
    • Disposable
    • Reusable 
  • Injection Pens Dosage Outlook (Revenue, USD Billion, 2014 – 2025) 
    • Fixed
    • Variable
  • Injection Pens Application Outlook (Revenue, USD Billion, 2014 – 2025) 
    • Diabetes
      • Insulin
      • Non-insulin
    • Anaphylaxis
    • Osteoporosis
    • Growth hormone deficiency
    • Arthritis
    • Others
  • Injection Pens Regional Outlook (Revenue, USD Billion, 2014 – 2025) 
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • Greece
      • Denmark
      • Spain
      • Norway
      • Belgium
      • Austria
    • Asia Pacific
      • Japan
      • China
      • India
      • Thailand
      • Australia
      • Singapore
      • Malaysia
      • Sri Lanka
      • Bangladesh
      • South Korea
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • MEA
      • UAE
      • Saudi Arabia
      • South Africa
      • Qatar
      • Kuwait

Explore the BI enabled intuitive market research database, Grand View Compass, by Grand View Research, Inc.

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

SAN FRANCISCO, November 20, 2018 /PRNewswire/ —

Read Full Article

German Environmental Prize awarded to marine biologist Antje Boetius and a team of wastewater experts from Leipzig

The German Environmental Foundation (DBU) has awarded the German Environmental Prize for the 26th time. Today in Erfurt, German President Frank-Walter Steinmeier and the Head of the Board of Trustees of the DBU and Parliamentary State Secretary at the Federal Ministry for the Environment, Rita Schwarzelühr-Sutter, presented marine biologist Antje Boetius (51, Bremerhaven) and an interdisciplinary team of wastewater experts from Leipzig that includes Roland A. Müller (55), Manfred van Afferden (57), Mi-Yong Lee (47) and Wolf-Michael Hirschfeld (70) with the 2018 German Environmental Prize the most prestigious independent environmental prize in Europe with a remuneration of EUR 500,000. With this year”s prize, the DBU is highlighting the importance of our oceans when it comes to protecting our climate, biodiversity and food supply, while also warning of the dangers of climate change, pollution and overfishing. This year”s prize also draws attention to the United Nations” call to action to provide the world”s population with safe drinking water and adequate sanitation by 2030, which would serve to significantly improve living conditions around the globe.   

Oceans act as the most important heat stores on the planet  

The DBU emphasized that oceans provide an important habitat for both flora and fauna, regulate the Earth”s climate and act as the most important heat stores on the planet. They have mitigated many of the effects of industrialisation and have absorbed a great deal of carbon dioxide and heat. In large part, they determine the Earth”s weather patterns as well because they often serve as the source of winds, storms and precipitation. And right now, our oceans are in critical condition. The melting of the polar ice caps, global warming, industrialisation, overfishing, and unimaginable quantities of waste all pose growing threats to this ecosystem. The number of so-called ‘dead zones’ in the world”s oceans – hypoxic or low-oxygen areas that are unable to support marine life – have grown by more than one-third since 1995. There are currently 400 of these dead zones around the world covering an area of more than 245,000 km[2], which is more than two-thirds the size of Germany.

A ground-breaking step for better living conditions for local populations 

This is also due, in part, to the fact that 80 to 90 per cent of wastewater in developing countries is discharged untreated directly into rivers, lakes and the oceans. The DBU has called the implementation a functioning, manageable, low-maintenance, cost- and energy-efficient sanitation sector in these countries a ground-breaking step in terms of improving the lives of the people currently living these countries, as well as the lives of their children and their children”s children. At the same time, there is still so much we do not know about the oceans” ecosystems, and it is vital that we close these gaps in our knowledge in order to understand the connection between microbial diversity in the deep sea and global shifts such as climate change. According to the DBU, we must first understand these processes in order to understand the global climate cycle and act on these findings.

Demonstrating the impact of deep-sea bacteria on the global climate  

Antje Boetius, deep-sea and polar researcher and Director of the Alfred Wegener Institute”s Helmholtz Centre for Polar and Marine Research, was lauded as an outstanding scientist with an extraordinary talent for understanding systemic processes in the world”s oceans from an interdisciplinary perspective and for conveying the relationships between them. Through her research, she has demonstrated the impact of deep-sea bacteria on the global climate: these bacteria ensure that only part of the harmful methane gas trapped in the ocean can escape into the atmosphere, thus preventing the planet from heating even faster. The marine biologist, ecosystem researcher and science communicator has repeatedly proven that human activity can be detected in the farthest reaches of the Earth.

Protecting a yet-unexplored world against destructive deep-sea mining practices  

In Boetius” view, along with climate change, the global fishing industry has already seriously altered the world”s oceans. Her aim is to ensure that the yet-unexplored world of the deep sea does not fall victim to destructive deep-sea mining practices required to mine raw materials such as manganese, iron, cobalt and rare metals. Our oceans must be understood as part of our planet and of our society as a whole, and thus as a crucial aspect of the sustainability aims of the United Nations. The biological diversity in our oceans and polar regions are also an important resource for our future and must therefore be protected.

Pioneering work and capacity development in Jordan  

As advocates for water resource protection, the team around the group of researchers at the Environment and Biotechnology Centre of the Helmholtz Centre for Environmental Research (Müller, van Afferden, Lee) and Wolf-Michael Hirschfeld, the initiator of the Training and Demonstration Centre for Decentralized Sewage Treatment, was honoured for their pioneering work in the area of capacity development in Jordan. Jordan is one of the top three countries in the world most affected by water scarcity and, in recent years, its population has grown by nearly 70 per cent from 5.6 million to 9.5 million (2016) due to the influx of refugees from Syria. The team took an interdisciplinary scientific approach, worked in an advisory capacity in terms of economics, acted as intermediaries in terms of politics, helped to inform the general public, and also took an active role in the practical implementation of the project.

Water scarcity as a major cause of migration  

Decentralised, flexible wastewater management systems, which can also be used to supplement existing systems, allow wastewater to be treated at the point of origin while also protecting the groundwater from wastewater contamination and preserving drinking water as a resource. In order to realise this project, the team had to overcome not only the boundaries between the natural, engineering and social sciences, but above all the boundaries between research and practice. This project is crucial because around two billion people around the world are forced to use drinking water that is contaminated with faeces. Alongside poverty, a lack of economic prospects and a lack of political participation, difficult living conditions including water scarcity are one of the main causes of migration.

Background information: With the German Environmental Prize, which is being awarded this year for the 26th time, the German Environmental Foundation (DBU) recognizes the achievements of persons who have contributed to the protection and conservation of the environment in an exemplary way, or who will contribute to environmental relief in Germany in the future. The prize – which is independent and, with a prize amount of EUR 500,000, the richest prize of its kind in Europe – can be awarded for projects and individual measures, as well as to honour an individual”s lifetime achievements. Candidates for the German Environmental Prize are nominated to the DBU by groups such as employer”s associations and labour unions, churches, environmental organisations and nature conservancies, scientific associations and research councils, as well as media, trade and commercial associations. Individuals may not nominate themselves. A jury of independent, prominent experts from the fields of industry, science and technology as well as from various societal organisations is selected by the DBU Board of Trustees and makes a recommendation on who they feel should be awarded the prize for that year. The DBU Board of Trustees then makes the final decision. For more information on the 2018 prize winners, please see: https://www.dbu.de/123artikel37810_2442.html

Contact
Franz-Georg Elpers
– Press Officer –
Kerstin Heemann
Julie Milch
Gesa Wannick

DBU Contact
An der Bornau 2
49090 Osnabrück
Germany 
Phone: +49(0)541-9633-521
Fax: +49(0)541-9633-198
presse@dbu.de
http://www.dbu.de

ERFURT, Germany, October 28, 2018 /PRNewswire/ —

Read Full Article

German Environmental Prize awarded to marine biologist Antje Boetius and a team of wastewater experts from Leipzig

The German Environmental Foundation (DBU) has awarded the German Environmental Prize for the 26th time. Today in Erfurt, German President Frank-Walter Steinmeier and the Head of the Board of Trustees of the DBU and Parliamentary State Secretary at the Federal Ministry for the Environment, Rita Schwarzelühr-Sutter, presented marine biologist Antje Boetius (51, Bremerhaven) and an interdisciplinary team of wastewater experts from Leipzig that includes Roland A. Müller (55), Manfred van Afferden (57), Mi-Yong Lee (47) and Wolf-Michael Hirschfeld (70) with the 2018 German Environmental Prize the most prestigious independent environmental prize in Europe with a remuneration of EUR 500,000. With this year”s prize, the DBU is highlighting the importance of our oceans when it comes to protecting our climate, biodiversity and food supply, while also warning of the dangers of climate change, pollution and overfishing. This year”s prize also draws attention to the United Nations” call to action to provide the world”s population with safe drinking water and adequate sanitation by 2030, which would serve to significantly improve living conditions around the globe.   

Oceans act as the most important heat stores on the planet  

The DBU emphasized that oceans provide an important habitat for both flora and fauna, regulate the Earth”s climate and act as the most important heat stores on the planet. They have mitigated many of the effects of industrialisation and have absorbed a great deal of carbon dioxide and heat. In large part, they determine the Earth”s weather patterns as well because they often serve as the source of winds, storms and precipitation. And right now, our oceans are in critical condition. The melting of the polar ice caps, global warming, industrialisation, overfishing, and unimaginable quantities of waste all pose growing threats to this ecosystem. The number of so-called ‘dead zones’ in the world”s oceans – hypoxic or low-oxygen areas that are unable to support marine life – have grown by more than one-third since 1995. There are currently 400 of these dead zones around the world covering an area of more than 245,000 km[2], which is more than two-thirds the size of Germany.

A ground-breaking step for better living conditions for local populations 

This is also due, in part, to the fact that 80 to 90 per cent of wastewater in developing countries is discharged untreated directly into rivers, lakes and the oceans. The DBU has called the implementation a functioning, manageable, low-maintenance, cost- and energy-efficient sanitation sector in these countries a ground-breaking step in terms of improving the lives of the people currently living these countries, as well as the lives of their children and their children”s children. At the same time, there is still so much we do not know about the oceans” ecosystems, and it is vital that we close these gaps in our knowledge in order to understand the connection between microbial diversity in the deep sea and global shifts such as climate change. According to the DBU, we must first understand these processes in order to understand the global climate cycle and act on these findings.

Demonstrating the impact of deep-sea bacteria on the global climate  

Antje Boetius, deep-sea and polar researcher and Director of the Alfred Wegener Institute”s Helmholtz Centre for Polar and Marine Research, was lauded as an outstanding scientist with an extraordinary talent for understanding systemic processes in the world”s oceans from an interdisciplinary perspective and for conveying the relationships between them. Through her research, she has demonstrated the impact of deep-sea bacteria on the global climate: these bacteria ensure that only part of the harmful methane gas trapped in the ocean can escape into the atmosphere, thus preventing the planet from heating even faster. The marine biologist, ecosystem researcher and science communicator has repeatedly proven that human activity can be detected in the farthest reaches of the Earth.

Protecting a yet-unexplored world against destructive deep-sea mining practices  

In Boetius” view, along with climate change, the global fishing industry has already seriously altered the world”s oceans. Her aim is to ensure that the yet-unexplored world of the deep sea does not fall victim to destructive deep-sea mining practices required to mine raw materials such as manganese, iron, cobalt and rare metals. Our oceans must be understood as part of our planet and of our society as a whole, and thus as a crucial aspect of the sustainability aims of the United Nations. The biological diversity in our oceans and polar regions are also an important resource for our future and must therefore be protected.

Pioneering work and capacity development in Jordan  

As advocates for water resource protection, the team around the group of researchers at the Environment and Biotechnology Centre of the Helmholtz Centre for Environmental Research (Müller, van Afferden, Lee) and Wolf-Michael Hirschfeld, the initiator of the Training and Demonstration Centre for Decentralized Sewage Treatment, was honoured for their pioneering work in the area of capacity development in Jordan. Jordan is one of the top three countries in the world most affected by water scarcity and, in recent years, its population has grown by nearly 70 per cent from 5.6 million to 9.5 million (2016) due to the influx of refugees from Syria. The team took an interdisciplinary scientific approach, worked in an advisory capacity in terms of economics, acted as intermediaries in terms of politics, helped to inform the general public, and also took an active role in the practical implementation of the project.

Water scarcity as a major cause of migration  

Decentralised, flexible wastewater management systems, which can also be used to supplement existing systems, allow wastewater to be treated at the point of origin while also protecting the groundwater from wastewater contamination and preserving drinking water as a resource. In order to realise this project, the team had to overcome not only the boundaries between the natural, engineering and social sciences, but above all the boundaries between research and practice. This project is crucial because around two billion people around the world are forced to use drinking water that is contaminated with faeces. Alongside poverty, a lack of economic prospects and a lack of political participation, difficult living conditions including water scarcity are one of the main causes of migration.

Background information: With the German Environmental Prize, which is being awarded this year for the 26th time, the German Environmental Foundation (DBU) recognizes the achievements of persons who have contributed to the protection and conservation of the environment in an exemplary way, or who will contribute to environmental relief in Germany in the future. The prize – which is independent and, with a prize amount of EUR 500,000, the richest prize of its kind in Europe – can be awarded for projects and individual measures, as well as to honour an individual”s lifetime achievements. Candidates for the German Environmental Prize are nominated to the DBU by groups such as employer”s associations and labour unions, churches, environmental organisations and nature conservancies, scientific associations and research councils, as well as media, trade and commercial associations. Individuals may not nominate themselves. A jury of independent, prominent experts from the fields of industry, science and technology as well as from various societal organisations is selected by the DBU Board of Trustees and makes a recommendation on who they feel should be awarded the prize for that year. The DBU Board of Trustees then makes the final decision. For more information on the 2018 prize winners, please see: https://www.dbu.de/123artikel37810_2442.html

Contact
Franz-Georg Elpers
– Press Officer –
Kerstin Heemann
Julie Milch
Gesa Wannick

DBU Contact
An der Bornau 2
49090 Osnabrück
Germany 
Phone: +49(0)541-9633-521
Fax: +49(0)541-9633-198
presse@dbu.de
http://www.dbu.de

ERFURT, Germany, October 28, 2018 /PRNewswire/ —

Read Full Article

Integrated Cannabis Company, Inc. (CSE: ICAN) (OTCQB: ICNAF) (‘Integrated Cannabis‘), is pleased to announce the signing of a Letter of Intent (the ‘LOI‘) to acquire all of the issued and outstanding securities of Critical Mass Industries, LLC (‘CMI‘), a Colorado-based cannabis leader operating successfully for nearly 10-years under the brands Good Meds ( http://www.GoodMeds.com ) and BOSM Labs (http://www.BosmLabs.com ) (the ‘Proposed Transaction‘).  

The combination of valuable Intellectual Property (‘IP‘), branding opportunities associated with the truly unique nearly decade long existence of Good Meds along with the management expertise from the CMI team will be utilized by Integrated Cannabis to establish new verticals in the cannabis space both domestically and in emerging global markets. CMI has over 100 elite cannabis strains, which will contribute proprietary cultivation and extraction methods to Integrated Cannabis. All of the combined assets will provide Integrated Cannabis organic growth along with a pathway toward acquisition of existing licensees and the licensing of the Company”s IP and Brands throughout the globe via key strategic alliances.

Additionally, the team has extensive knowledge and resources relating to the high growth Cannabidiol (CBD) sector. Deploying this expertise to furthering the commercialization of the X-SPRAYS brand of CBD sprays demonstrates one of the many naturally synergistic opportunities the company will realize. Finally, and importantly, the team envisions widely commercializing the uniquely valuable Good Meds name, legacy and reputation via consistently branded retail stores throughout the globe. Management believes capitalizing on this opportunity will place the company in a true leadership position as a trusted and consistent cannabis provider.

‘The acquisition of CMI”s unique assets, decade of experience in the first fully regulated marketplace and the human resource component realized from the teams depth of knowledge in the sector will immediately supply both significant revenue and expertise to Integrated Cannabis. We are excited to include this new platform and the amazing team of professionals will serve as another key element toward realizing our global expansion,’ said Dr. Clive Spray, CSO Integrated Cannabis.

Staying with Integrated Cannabis” long-held position surrounding business operations in the United States, this transaction would not have been pursued were it not in clear accordance with current US federal law. Integrated Cannabis, through a newly formed subsidiary, will employ CMI”s assets and personnel to conduct R&D and licensing. There will be no production or sale of products resulting from such R&D or licensing in the United States unless and until it would be federally legal to do so.

Integrated Cannabis has paid a non-refundable deposit of US$250,000 upon signing the LOI and, at closing, will pay an additional US$2,500,000 and issue 2,300,000 Integrated Cannabis common shares to the shareholders of CMI in exchange for the securities being acquired.

CMI reported revenue in excess of USD $7 million in 2017 to the Colorado Department of Revenue. The Colorado Department of Revenue is responsible for all sales and excise taxes related to the cannabis industry in the State.

The LOI sets out certain terms and conditions pursuant to which the Proposed Transaction will be completed. The Proposed Transaction remains subject to certain closing conditions including, without limitation, the (a) completion of customary due diligence, (b) negotiation and execution of a definitive agreement (‘Definitive Agreement‘), (c) receipt of a valuation of CMI (d) the receipt of all required regulatory, board and third party approvals, and (e) any other conditions to closing contained in the Definitive Agreement. There can be no guarantees that the Proposed Transaction will be completed as contemplated or at all. The Proposed Transaction is anticipated to close in November 2018. Integrated Cannabis anticipates that some of the shares issued pursuant to the Proposed Transaction may be subject to escrow requirements and/or hold periods required by CSE policies and applicable securities laws.

As a result of John Knapp, the Chief Executive Officer of Integrated Cannabis, being a control person of CMI, the Proposed Transaction constitutes a related party transaction under Canadian Multilateral Instrument 61-101 (‘MI 61-101‘). Integrated Cannabis is relying on exemptions from the formal valuation and minority approval requirements of MI 61-101 based on a determination that the securities of Integrated Cannabis are listed on the Canadian Securities Exchange and that neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the Proposed Transaction, insofar as it involves interested parties, exceeds 25% of the market capitalization of Integrated Cannabis.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. None of the securities to be issued pursuant to the Proposed Transaction have been or will be registered under the U.S. Securities Act of 1933, as amended (the ‘U.S. Securities Act‘), or any state securities laws, and any securities issued pursuant to the Proposed Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Rule 506(b) of Regulation D and/or Section 4(a)(2) of the U.S. Securities Act and applicable exemptions under state securities laws. In addition, the securities to be issued pursuant to the Proposed Transaction under an exemption from the registration requirements of the U.S. Securities Act will be ‘restricted securities’ as defined under Rule 144(a)(3) of the U.S. Securities Act and will contain the appropriate restrictive legend as required under the U.S. Securities Act. Any public offering of securities of Integrated Cannabis to be made in the United States must be made by means of a prospectus containing detailed information about Integrated Cannabis and management, as well as financial statements.

About Integrated Cannabis Company 

Integrated Cannabis Company, Inc. is comprised of dedicated scientists and product engineers who are passionate about health and creating health and lifestyle products utilizing advanced delivery systems and formulations. For more information, please visit the company”s website at: http://www.x-sprays.com .

ON BEHALF OF THE BOARD 

John Knapp
Chief Executive Officer

The CSE does not accept responsibility for the adequacy or accuracy of this release.   

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. 

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. 

For further information, please contact:
Eugene Beukman
Telephone: 604-687-2038
Email: info@cnrpmining.com

VANCOUVER, British Columbia, October 19, 2018 /PRNewswire/ —

Read Full Article